Details for Patent: 5,972,882
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
Summary for Patent: 5,972,882
Title: | Treatment of polycystic kidney disease using vasopressin V.sub.2 receptor antagonists |
Abstract: | The present invention is directed to the novel treatment of ARPKD and ADPKD by administering a pharmacologically effective amount of a V.sub.2 receptor antagonist. Orally active V.sub.2 receptor antagonists such as OPC-31260, OPC-41061, SR121463A and VPA-985 are administered alone, or in combination to mammalian PKD subjects to reduce the cAMP generated by the increased expression of AVP-V.sub.2 receptor, AQP2 and AQP3, thereby reducing and/or preventing cyst enlargement. |
Inventor(s): | Gattone, II; Vincent H. (Overland Park, KS) |
Assignee: | University of Kansas Medical Center (Kansas City, KS) |
Application Number: | 09/211,396 |
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 5,972,882
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |